drugset / Trial / NCT01322438

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

NCT01322438

Phase 1 Completed 24 enrolled Bayer
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to see if giving rifampin, a marketed antibiotic, changes how your body absorbs and distributes BAY73-4506.

Timeline

Start
2011-03
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Regorafenib Small molecule 160 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications